RCE.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 03:11):

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom...

Stats
Dzisiejszy wolumen	5 875.00
Średni wolumen	170 672
Kapitalizacja rynkowa	130.53M
EPS	$0 ( 2024-02-25 )
Następna data zysków	( $0 ) 2024-07-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.67
ATR14	$0.00600 (0.94%)

Recce Pharmaceuticals Ltd Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Recce Pharmaceuticals Ltd Finanse

Annual	2023
Przychody:	$4.37M
Zysk brutto:	$4.15M (95.03 %)
EPS:	$-0.0744

FY	2023
Przychody:	$4.37M
Zysk brutto:	$4.15M (95.03 %)
EPS:	$-0.0744

FY	2022
Przychody:	$3.08M
Zysk brutto:	$2.90M (93.92 %)
EPS:	$-0.0625

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.143

Financial Reports:

No articles found.

Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.